Patients affected by SLE and other autoimmune disorders have higher BLyS and APRIL levels, thus suggesting that atacicept may be more efficient because of its dual blockade and its ability to target long-living plasma cells in addition to B cells39,44. This evidence concerns the gene TNFSF13B and systemic lupus erythematosus.